Biosino Bio-technology (08247.HK) announced on August 29th that as of June 30th, 2024, the company achieved revenue of RMB 0.134 billion, a decrease of 3.8% compared to the same period last year; gross profit was RMB 58.531 million, a decrease of 12.2% compared to the same period last year; the company's net loss attributable to shareholders was RMB 13.182 million, compared to RMB 5.423 million in the same period last year; basic loss per share was RMB 0.091.
中生北控生物科技(08247.HK):上半年母公司拥有人应占亏损1318.2万元
Biosino Bio-Tec (08247.HK): The loss attributable to the parent company in the first half of the year was 13.182 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.